Q-omics provides the consensus-scored TRIM77BP profile across patient tissues and cancer cell-line models. TRIM77BP expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TRIM77BP is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, TRIM77BP RNA expression shows 5,973 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KIRC as cancer lineages where TRIM77BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM77BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM77BP survival associations across molecular data types. TRIM77BP RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM77BP RNA expression–survival associations across cancer types. High TRIM77BP expression shows unfavorable associations in STAD, LUAD, UCEC, SARC, LUSC and GBM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for TRIM77BP RNA expression.
This table summarizes TRIM77BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM77BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM77BP shows higher tumor expression in KIRC. The KIRC box plot shows higher TRIM77BP RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .047).
This table shows molecular features associated with TRIM77BP in patient tissues and cancer cell lines. In patient samples, TRIM77BP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
